外照射加速部分乳腺照射每日分割至40 Gy耐受良好且局部有效
研究前瞻性纳入106例保乳术后淋巴结阴性乳腺导管原位癌或浸润性癌患者,接受三维适形外照射加速部分乳腺照射(APBI)40 Gy分10次每日照射。中位随访58个月,16例(15%)出现≥2级皮肤毒性,仅2例3级毒性,3例乳腺癌复发,99%患者美容效果优/良。
要点
- APBI 40 Gy分10次每日照射,≥2级皮肤毒性16/106(15%),3级毒性仅2例。
- 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,限制乳腺V20<45%可能改善耐受性。
- 3例乳腺癌复发:原象限局部1例(3年)、同侧不同象限1例(5年)、远处转移1例(2年)。
核心结论
- 在适当选择的早期乳腺癌患者中,APBI 40 Gy分10次每日照射耐受良好,99%患者报告美容效果优/良。
- 应仔细限制计划靶体积和乳腺V20以减少局部并发症,需更长随访确定疗效和后续局部复发率。
研究设计与样本
- 前瞻性研究,2010年至2014年纳入106例保乳术后淋巴结阴性乳腺浸润性或原位癌患者,接受三维适形外照射APBI 40 Gy分10次每日照射。
主要发现
- 中位年龄62岁(范围39-85),中位随访58个月。
- 106例中16例(15%)发生≥2级皮肤毒性,最常见为放疗后4-9周急性皮肤改变,包括2级红斑2例(1.8%)和皮肤颜色改变4例(3.8%)。
- 仅报告2例3级毒性,包括1例放疗后急性湿性脱屑和1例2年时纤维化。
- 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,有证据表明限制乳腺V20<45%可能改善耐受性。
- 共3例乳腺癌复发:原象限局部复发1例(APBI后3年)、同侧不同象限1例(APBI后5年)、远处转移1例(APBI后2年)。
关键数值与推荐
- APBI总剂量40 Gy分10次每日照射。
- 计划靶体积和乳腺V20显著预测皮肤/皮下毒性,限制乳腺V20<45%可能改善耐受性。
临床怎么用
- 在适当选择的早期乳腺癌患者中,APBI 40 Gy分10次每日照射耐受良好,99%患者美容效果优/良。
- 应仔细限制计划靶体积和乳腺V20以限制局部并发症。
局限性
- 需更长随访确定疗效和后续局部复发率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most studies examining accelerated partial breast irradiation (APBI) have used twice-daily fractionation. Cosmesis with this approach has produced mixed results, and the optimal fractionation scheme remains unknown. We sought to evaluate the safety and efficacy of APBI with a total dose of 40 Gy in 10 daily fractions. METHODS AND MATERIALS: Between 2010 and 2014, we prospectively enrolled 106 patients to receive APBI after lumpectomy for invasive or in situ node-negative breast cancer. Radiation was administered via 3-dimensional conformal techniques. RESULTS: The median age was 62 years (range, 39-85), and all patients underwent APBI per protocol. With a median follow-up of 58 months, we evaluated patient-reported local toxicity and recurrence outcomes. Of 106 patients, 16 (15%) experienced grade ≥2 skin toxicity. The most common significant toxicities were acute cutaneous changes at 4 to 9 weeks after radiation therapy, including grade 2 erythema in 2 patients (1.8%) and skin color changes in 4 patients (3.8%). Only 2 instances of grade 3 toxicity were reported, including 1 patient with acute moist desquamation after radiation therapy and another with fibrosis at 2 years. Planning target volume and breast V20 were significantly predictive of skin/subcutaneous toxicity, with evidence that limiting breast V20 to <45% may improve tolerability. Overall, 3 breast cancer recurrences arose: 1 local recurrence in the original quadrant (3 years after APBI), 1 in a different ipsilateral quadrant (5 years after APBI), and 1 with distant disease 2 years after APBI. CONCLUSIONS: In an appropriately selected group of patients with early stage breast cancer, APBI to a dose of 40 Gy in 10 daily fractions was well tolerated, with most patients (99%) reporting excellent/good cosmesis. Planning target volume and breast V20 should be carefully constrained to limit local morbidity. Longer follow-up will be needed to establish efficacy and subsequent local recurrence rates.
引用
- Braunstein LZ, Thor M, Flynn J, et al. Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851350. doi:10.1016/j.ijrobp.2019.02.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。